Clinical Trial Update: Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ceritinib with stereotactic ablative radiation in ALK-positive non-small cell lung cancer was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ceritinib (ceritinib)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: ALK-positive Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-12-17